27 results on '"Márquez Peláez, Sergio"'
Search Results
2. 1166. The Cost-Effectiveness Evidence of Enhanced Influenza Vaccines in Adults ≥65 Years of Age: A Literature Review and Decision-Making Implications
- Author
-
Giglio, David FismanNorberto, primary, Márquez-Peláez, Sergio, additional, Nguyen, Van, additional, Postma, Maarten, additional, Pugliese, Andrea, additional, Ruiz-Aragón, Jesús, additional, urueña, Analia, additional, and Mould-Quevedo, Joaquin F, additional
- Published
- 2023
- Full Text
- View/download PDF
3. Contributions of cost-effectiveness analyses (CEA) to influenza vaccination policy for older adults in Europe
- Author
-
Chicoye, Annie, primary, Crépey, Pascal, additional, Nguyen, Van Hung, additional, Márquez-Peláez, Sergio, additional, Postma, Maarten, additional, Pugliese, Andrea, additional, Ruiz-Aragón, Jesús, additional, and Mould-Quevedo, Joaquin, additional
- Published
- 2023
- Full Text
- View/download PDF
4. An Economic Comparison in the Elderly of Adjuvanted Quadrivalent Influenza Vaccine with Recombinant Quadrivalent Influenza Vaccine in Spain
- Author
-
Ruiz-Aragón, Jesús, primary and Márquez-Peláez, Sergio, additional
- Published
- 2023
- Full Text
- View/download PDF
5. An Economic Evaluation of the Adjuvanted Quadrivalent Influenza Vaccine Compared with Standard-Dose Quadrivalent Influenza Vaccine in the Spanish Older Adult Population
- Author
-
Fochesato, Anna, primary, Sottile, Sara, additional, Pugliese, Andrea, additional, Márquez-Peláez, Sergio, additional, Toro-Diaz, Hector, additional, Gani, Ray, additional, Alvarez, Piedad, additional, and Ruiz-Aragón, Jesús, additional
- Published
- 2022
- Full Text
- View/download PDF
6. Real-World Evidence in Cost-Effectiveness Analysis of Enhanced Influenza Vaccines in Adults ≥ 65 Years of Age: Literature Review and Expert Opinion.
- Author
-
Postma, Maarten, Fisman, David, Giglio, Norberto, Márquez-Peláez, Sergio, Nguyen, Van Hung, Pugliese, Andrea, Ruiz-Aragón, Jesús, Urueña, Analia, and Mould-Quevedo, Joaquin
- Subjects
LITERATURE reviews ,INFLUENZA vaccines ,CAROTID endarterectomy ,OLDER people ,CARCINOEMBRYONIC antigen ,COST effectiveness ,VACCINE effectiveness - Abstract
Influenza vaccination can benefit most populations, including adults ≥ 65 years of age, who are at greater risk of influenza-related complications. In many countries, enhanced vaccines, such as adjuvanted, high-dose, and recombinant trivalent/quadrivalent influenza vaccines (aTIV/aQIV, HD-TIV/HD-QIV, and QIVr, respectively), are recommended in older populations to provide higher immunogenicity and increased relative vaccine efficacy/effectiveness (rVE) than standard-dose vaccines. This review explores how efficacy and effectiveness data from randomized controlled trials and real-world evidence (RWE) are used in economic evaluations. Findings from published cost-effectiveness analyses (CEA) on enhanced influenza vaccines for older adults are summarized, and the assumptions and approaches used in these CEA are assessed alongside discussion of the importance of RWE in CEA. Results from many CEA showed that adjuvanted and high-dose enhanced vaccines were cost-effective compared with standard vaccines, and that differences in rVE estimates and acquisition price may drive differences in cost-effectiveness estimates between enhanced vaccines. Overall, RWE and CEA provide clinical and economic rationale for enhanced vaccine use in people ≥ 65 years of age, an at-risk population with substantial burden of disease. Countries that consider RWE when making vaccine recommendations have preferentially recommended aTIV/aQIV, as well as HD-TIV/HD-QIV and QIVr, to protect older individuals. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
7. Control ambulatorio de los pacientes con trombosis venosa profunda y cáncer: estudio de seguridad, costes e impacto presupuestario
- Author
-
Jara Palomares, Luis, Caballero Eraso, Candela, Elías Hernández, Teresa, Ferrer Galván, Marta, Márquez Peláez, Sergio, Cayuela, Aurelio, Alfaro, María José, Barrot Cortés, Emilia, and Otero Candelera, Remedios
- Published
- 2012
- Full Text
- View/download PDF
8. Cost-Effectiveness and Burden of Disease for Adjuvanted Quadrivalent Influenza Vaccines Compared to High-Dose Quadrivalent Influenza Vaccines in Elderly Patients in Spain
- Author
-
Ruiz-Aragón, Jesús, primary, Márquez-Peláez, Sergio, additional, Gani, Ray, additional, Alvarez, Piedad, additional, and Guerrero-Luduena, Richard, additional
- Published
- 2022
- Full Text
- View/download PDF
9. Efectividad clínica, seguridad y evaluación económica del cribado poblacional de hepatitis C. Revisión Sistemática.
- Author
-
Llanos-Méndez, Aurora, primary, Molina-Linde, Juan Máximo, additional, Cerezo-Hidalgo, Clara, additional, and Márquez-Peláez, Sergio, additional
- Published
- 2022
- Full Text
- View/download PDF
10. Evaluacion del sistema de navegacion magnetica intracardiaca Niobe[R], revision sistematica de la literatura cientifica
- Author
-
Ruiz-Aragón, Jesús, Molina-Linde, Juan Máximo, Márquez-Peláez, Sergio, and Rodríguez-López, Rocío
- Published
- 2011
11. Evaluacion de las tecnicas de amplificacion genomica (NAT) para el tamizaje de hepatitis B en donantes de sangre. Revision sistematica
- Author
-
Ruiz-Aragón, Jesús and Márquez-Peláez, Sergio
- Published
- 2010
12. Trasplante renal de donante vivo incompatible: Actualización
- Author
-
Márquez Peláez, Sergio, Blasco Amaro, Juan A., Aguado Romeo, María J., [Márquez Peláez,S, Blasco Amaro,JA, and Aguado Romeo,MJ] AETSA Evaluación de Tecnologías Sanitarias de Andalucía.
- Subjects
Blood group incompatibility ,Kidney diseases ,Diseases::Male Urogenital Diseases::Urologic Diseases::Kidney Diseases [Medical Subject Headings] ,Technology assessment, biomedical ,Diseases::Hemic and Lymphatic Diseases::Hematologic Diseases::Blood Group Incompatibility [Medical Subject Headings] ,Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Renal Replacement Therapy::Kidney Transplantation [Medical Subject Headings] ,Health Care::Health Care Quality, Access, and Evaluation::Quality of Health Care::Health Care Evaluation Mechanisms::Technology Assessment, Biomedical [Medical Subject Headings] ,Evaluación de la tecnología biomédica ,Kidney transplantation ,Supervivencia del injerto ,Enfermedades renales ,Tissue donors ,Donantes de tejidos ,Persons::Persons::Tissue Donors [Medical Subject Headings] ,Trasplante de riñón ,Incompatibilidad de grupos sanguíneos - Abstract
El trasplante renal de donante vivo incompatible (TRDVI) es la donación, por parte de un donante vivo, de un riñón que presenta incompatibilidad sanguínea ABO y/o HLA con el receptor. En un informe anterior, similar a este, publicado en 2014 por AETSA, se consideró que la evidencia era escasa y de baja calidad, aunque con resultados concordantes, en términos de la supervivencia del injerto y la supervivencia y mortalidad de los pacientes sometidos a este tipo de trasplante. Hemos considerado recomendable una actualización ese informe de 2014 puesto que se han publicado numerosos estudios, e incluso una evaluación económica, sobre este asunto. A pesar de la variabilidad y la mediana calidad de los estudios primarios que han sido valorados en esta ocasión, los resultados mostrados son consistentes y se mantienen las afirmaciones del informe anterior de 2014. La supervivencia del injerto y de los pacientes sometidos a TRDVI con incompatibilidad HLA son altas y comparables, aunque ligeramente inferiores, en general, a los valores ofrecidos por los trasplantes ABOi. En los estudios sobre ABOi, los resultados recopilados sobre ambas variables de supervivencia mantienen las afirmaciones del informe anterior, manteniéndose en valores altos y comparables a trasplantes ABOc. Yes
- Published
- 2021
13. Adaptación informe 'C-reactive protein point-of-care testing (CRP-poct) to guide antibiotic prescribing in primary care settings for acute respiratory tract infections'. Executive summary
- Author
-
Blasco-Amaro, Juan Antonio, Márquez-Peláez, Sergio, Castro-Campos, José Luis, [Blasco-Amaro,JA, Márquez-Peláez,S, Castro-Campos,JL] AETSA Evaluación de Tecnologías Sanitarias de Andalucía., and Este documento ha sido realizado por la AETSA, Evaluación de Tecnologías Sanitarias de Andalucía en el marco de la financiación del Ministerio de Sanidad, Consumo y Bienestar Social para el desarrollo de las actividades del Plan anual de Trabajo de la Red Española de Agencias de Evaluación de Tecnologías Sanitarias y Prestaciones del SNS, aprobado en el Pleno del Consejo Interterritorial del SNS de 15 de noviembre de 2018 (conforme al Acuerdo del Consejo de Ministros de 7 de diciembre de 2018)
- Subjects
Sistemas de atención de puntos ,Atención primaria de salud ,Diseases::Respiratory Tract Diseases::Respiratory Tract Infections [Medical Subject Headings] ,Infecciones del sistema respiratorio ,Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::C-Reactive Protein [Medical Subject Headings] ,Proteína C reactiva ,Health Care::Health Services Administration::Patient Care Management::Comprehensive Health Care::Primary Health Care [Medical Subject Headings] - Abstract
Se ha realizado un informe de evaluación de la eficacia, seguridad y efectividad de la determinación de la proteína C reactiva a la cabecera del paciente para las infecciones agudas del tracto respiratorio en atención, a partir de la adopción del informe de EUnetHTA sobre la misma tecnología complementado con la adaptación al contexto español de algunos de sus apartados incluida una revisión de la evaluación económica de la tecnología. Yes
- Published
- 2020
14. Criterios de calidad para la red española de agencias de evaluación de tecnologías sanitarias del sistema nacional de salud
- Author
-
Márquez Peláez, Sergio, Viguera Guerra, Isabel, Isabel Gómez, Rebeca, Castro Campos, José Luis, [Márquez Peláez,S, Viguera Guerra,I, Isabel Gómez,R, and Castro Campos,JL] AETSA Evaluación de Tecnologías Sanitarias de Andalucía.
- Subjects
Evaluación de la tecnología biomédica ,Health Care::Health Care Quality, Access, and Evaluation::Quality Assurance, Health Care::Total Quality Management [Medical Subject Headings] ,Gestión de la calidad ,Health Care::Health Care Quality, Access, and Evaluation::Quality Assurance, Health Care [Medical Subject Headings] ,Agencias de los sistemas de salud ,Garantía de la calidad de atención de salud ,Health Care::Health Care Quality, Access, and Evaluation::Quality of Health Care::Health Care Evaluation Mechanisms::Technology Assessment, Biomedical [Medical Subject Headings] ,Health Care::Health Care Economics and Organizations::Organizations::Health Planning Organizations::State Health Planning and Development Agencies::Health Systems Agencies [Medical Subject Headings] - Abstract
Mediante la búsqueda de literatura y formación de un grupo de trabajo se planteó el objetivo de desarrollar una herramienta de autoevaluación de calidad el proceso de gestión de la propia RedETS y del Pleno de Consejo de la Red en todas sus funciones. La literatura localiza sobre calidad para redes de evaluación es limitada, si bien permitió, junto con la experiencia acumulada del informe anterior desarrollado en 2016, elaborar 26 estándares y consensuarlos para crear la herramienta final resultado de este informe. Dicha herramienta puede ser útil y complementaria a la ya creada para los nodos de la RedETS, se espera que mejore el proceso de autoevaluación de la calidad global de la red, así como que contribuya al asesoramiento y apoyo a otras redes de ETS que pretendan implantar sistemas de calidad. Yes
- Published
- 2020
15. Guía para la elaboración de recomendaciones basadas en análisis de decisión multicriterio
- Author
-
Márquez Peláez, Sergio, Espín Balbino, Jaime, Olry de Labry Lima, Antonio, Benítez Hidalgo, Vivian, Grupo de trabajo RedETS para CDMA, [Márquez Peláez,S] AETSA, Evaluación de Tecnologías Sanitarias de Andalucía. [Espín Balbino,J, Olry de Labry Lima,A, Benítez Hidalgo,V] Escuela Andaluza de Salud Pública (EASP). [Olry de Labry Lima,A] CIBER en Epidemiología y Salud Pública (CIBERESP)., and Este documento ha sido realizado por la Agencia de Evaluación de Tecnologías Sanitarias de Andalucía en el marco de la financiación del Ministerio de Sanidad, Servicios Sociales e Igualdad para el desarrollo de las actividades del Plan anual de Trabajo de la Red Española de Agencias de Evaluación de Tecnologías Sanitarias y Prestaciones del SNS, aprobado en el Pleno del Consejo Interterritorial del SNS de 8 de noviembre de 2017 (conforme al Acuerdo del Consejo de Ministros de 1 de diciembre de 2017).
- Subjects
Análisis multivariante ,Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Analysis of Variance::Multivariate Analysis [Medical Subject Headings] ,Técnicas de apoyo para la decisión ,Análisis toma decisión ,Psychiatry and Psychology::Psychological Phenomena and Processes::Mental Processes::Thinking::Decision Making [Medical Subject Headings] ,Multicriterio ,Toma de decisiones ,Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Decision Support Techniques [Medical Subject Headings] - Abstract
La evaluación de tecnologías conlleva un proceso sistemático de investigación mediante el cual se identifica, evalúa, selecciona y sintetiza la información científica disponible sobre la eficacia, seguridad y eficiencia de una tecnología sanitaria en comparación con la intervención de referencia, así como el impacto de uso a nivel económico, organizacional, ético y social. El Análisis de Decisión Multicriterio (en adelante ADMC o MCDA, del inglés: MultiCriteria Decision Analysis) es un conjunto de métodos que, de manera explícita y sistemática, permite tener en cuenta criterios adicionales. Esto permite desarrollar un proceso de toma de decisiones con una perspectiva más holística, haciendo explícitos los valores o dimensiones y su importancia relativa en este proceso. Yes
- Published
- 2020
16. Estudio observacional post-introducción de las pruebas predictivo/pronósticas en cáncer de mama del Sistema Sanitario Público de Andalucía (SSPA)
- Author
-
Benot López, Soledad, Noriega Barreda, Covadonga, Martínez Ferez, Isabel, Bayo Lozano, Eloísa, Márquez Peláez, Sergio, Abu Omar, Nadia, Aldana Espinal, Josefa M.ª, [Benot López,S, Martínez Ferez,I, Márquez Peláez,S] AETSA Evaluación de Tecnologías Sanitarias de Andalucía. [Noriega Barreda,C, Aldana Espinal,JM] Servicio Andaluz de Salud. [Bayo Lozano, E, and Abu Omar, N] Hospital Virgen Macarena.
- Subjects
Evaluación de la tecnología biomédica ,Diseases::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Disease Attributes::Recurrence [Medical Subject Headings] ,Biología molecular ,Disciplines and Occupations::Natural Science Disciplines::Biological Science Disciplines::Biology::Genetics::Molecular Biology [Medical Subject Headings] ,Evaluación de tecnologias sanitaria de Andalucía ,Pruebas genómicas ,Neoplasias de la mama ,Recurrencia ,Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Genetic Techniques::Genetic Testing [Medical Subject Headings] ,Pruebas genéticas ,Diseases::Neoplasms::Neoplasms by Site::Breast Neoplasms [Medical Subject Headings] ,Riesgo de recurrencia - Abstract
Este trabajo se lleva a cabo para dar respuesta a las siguientes preguntas de investigación: 1. ¿Se han seleccionado de manera adecuada a las pacientes candidatas a las pruebas genómicas en función de los criterios de inclusión establecidos? 2. ¿Los resultados de las plataformas genómicas modifican la decisión terapéutica del profesional? 3. ¿Qué implicaciones económicas suponen la incorporación de estas plataformas a la cartera de Servicios del SSPA? Yes
- Published
- 2019
17. Criterios de calidad y de buenas prácticas en organismos dedicados a la evaluación de tecnologías sanitarias: línea de desarrollos metodológicos de la Red Española de Agencias de Evaluación de Tecnologías Sanitarias y Prestaciones del SNS
- Author
-
Navarro Palenzuela, Carmen, Márquez Peláez, Sergio, Molina López, Teresa, Rodríguez López, Rocío, [Navarro Palenzuela,C, Márquez Peláez,S, Molina López,T, Rodríguez López,R] Evaluación de Tecnologías Sanitarias de Andalucía (AETSA)., and Este documento ha sido financiado por el Ministerio de Sanidad, Servicios Sociales e Igualdad, en el marco del plan anual de trabajo de la Red Española de Agencias de Evaluación de Tecnologías y Prestaciones del SNS, aprobado en el Pleno del Consejo Interterritorial de 13 de abril de 2016.
- Subjects
Geographical Locations::Geographic Locations::Europe::Spain [Medical Subject Headings] ,Revisión sistemática ,España ,Technology assessment, biomedical ,Methodology ,Estándares de referencia ,Health Care::Health Care Quality, Access, and Evaluation::Quality of Health Care::Health Care Evaluation Mechanisms::Technology Assessment, Biomedical [Medical Subject Headings] ,Metodología ,National organizations in science and technology ,Evaluación de la tecnología biomédica ,Health Care::Health Care Quality, Access, and Evaluation::Quality Assurance, Health Care::Total Quality Management [Medical Subject Headings] ,Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Weights and Measures::Reference Standards [Medical Subject Headings] ,Gestión de la calidad ,Health Care::Health Care Quality, Access, and Evaluation::Quality of Health Care::Health Care Evaluation Mechanisms::Evaluation Studies as Topic [Medical Subject Headings] ,Reference standards ,Quality management ,Organismos nacionales de ciencia y tecnología - Abstract
El objetivo de este proyecto es proporcionar una herramienta que recoja los criterios de calidad y buenas prácticas a seguir por las distintas agencias y organismos pertenecientes a Redets. Liderado por AETSA y con la participación de todos los nodos de Redets se desarrollaron 67 estándares de calidad agrupados en cuatro bloques y doce dimensiones de calidad. Yes
- Published
- 2017
18. PP037 Quality Criteria And Good Practices In The Health Technology Assessment Spanish Network
- Author
-
Márquez-Peláez, Sergio, primary, Navarro-Palenzuela, Carmen, additional, Molina-Lopez, Teresa, additional, del Mar Castellano-Zurera, María, additional, and Castro-Campos, José Luis, additional
- Published
- 2017
- Full Text
- View/download PDF
19. VP24 The Development Of A Quality Management Tool For Health Technology Assessment Agencies In Spain
- Author
-
Márquez-Peláez, Sergio, primary, Gutiérrez-Ibarluzea, Iñaki, additional, Asua, José, additional, Molina-Lopez, Teresa, additional, Castro-Campos, José Luis, additional, Garcia-Armesto, Sandra, additional, Bono-Vega, María, additional, Bugarín-González, Rosendo, additional, Riobóo, Janet Puñal, additional, Luengo-Matos, Setefilla, additional, Brezmes-Delgado, Ana, additional, Suton, Victoria Serra, additional, Reynolds, Jillian Margaret, additional, Gonzalez-Enriquez, Jesús, additional, Serrano-Aguilar, Pedro, additional, and Trujillo-Martin, M. Mar, additional
- Published
- 2017
- Full Text
- View/download PDF
20. Evaluación de la eficacia y seguridad de tigeciclina en el tratamiento de infecciones del tracto respiratorio: Revisión sistemática de la literatura científica
- Author
-
Moya Cordero, Patricia, Ruiz-Aragón, Jesús, Molina Linde, Juan Máximo, Márquez-Peláez, Sergio, and Motiva Sánchez, Virginia
- Subjects
community-acquired pneumonia ,systematic review ,nosocomial pneumonia ,revisión sistemática ,Tigeciclina ,neumonía nosocomial ,Tigecycline ,neumonía adquirida en la comunidad - Abstract
Introducción: Tigeciclina está indicada en el tratamiento de infecciones complicadas de piel, tejidos blandos e intra-abdominales. Su utilización podría extenderse para neumonías adquiridas en la comunidad (NAC) y neumonías hospitalarias (NH). El objetivo ha sido evaluar la eficacia y seguridad de tigeciclina en el tratamiento de infecciones respiratorias. Material y Métodos: Revisión sistemática (2012). Se realizaron búsquedas en MedLine, Embase, Cochrane Library, CRD y WOK. Se localizaron ensayos clínicos de adultos con infección respiratoria, tratados mediante tigeciclina. La calidad de los estudios se valoró mediante los criterios CASPe. Resultados: Se seleccionaron cuatro ensayos clínicos de calidad alta-moderada. Tres estudios incluyeron pacientes con NAC y un estudio a pacientes con NH. En pacientes con NAC la eficacia de tigeciclina (88,6-90,6%) fue no inferior a la de levofloxacina (85,3-87,2%). El "test de no inferioridad" fue estadísticamente significativo (p < 0,001). En el estudio de pacientes con NH, tigeciclina presentó una eficacia de 67,9% frente a 78,2% de imipenem/cilastatina. Los principales efectos adversos fueron gastrointestinales. Conclusiones: la eficacia de tigeciclina es no inferior a la de levofloxacina en pacientes con NAC, pero inferior a imipenem en pacientes con NH. Tigeciclina ha demostrado no inferioridad frente a los otros antimicrobianos testados. Tigeciclina demuestra tener un buen perfil de seguridad. Background: Tigecycline is indicated for the treatment of complicated skin infections, soft tissue and intraabdominal infections. Its use could be extended to community-acquired pneumonia (CAP) and hospital pneumonia (HN). The objective was to evaluate the efficacy and safety of tigecycline in the treatment of respiratory infections. Methods: systematic review (2012). Databases used were MEDLINE, EMBASE, Cochrane Library, CRD and WOK. We identified clinical trials of adults with respiratory infection, treated with tigecycline. The quality of the studies was assessed using CASPe checklist. Results: We selected four clinical trials of high-moderate quality. Three studies with patients with CAP and a trial with HN patients. In patients with CAP, efficacy of tigecycline (88.6 to 90.6%) was higher than levofloxacin (85.3 to 87.2%). The non inferiority testing was statistically significant (p < 0.001). In the study of patients with HN tigecycline showed an efficiency of 67.9% versus 78.2% for imipenem/cilastatin. Main adverse effects were gastrointestinal. Conclusions: The efficacy of tigecycline is non inferior than levofloxacin in patients with CAP, but less than imipenem in patients with HN. Tigecycline demonstrates noninferiority versus others tested antibiotics, and it shows a good safety profile.
- Published
- 2013
21. Evaluación de las técnicas de amplificación genómica (NAT) para el tamizaje de hepatitis B en donantes de sangre. Revisión sistemática.
- Author
-
Ruiz Aragón, Jesús, Márquez Peláez, Sergio, Ruiz Aragón, Jesús, and Márquez Peláez, Sergio
- Abstract
 Las nuevas técnicas de biología molecular, denominadas técnicas de amplificación del ADN genómico “nucleic acid testing” (NAT), permiten la detección de partículas del ADN viral de la hepatitis B, independientemente de la fase de la enfermedad. Estas técnicas aumentan la sensibilidad del tamizaje, así el riesgo de infección mediante transfusiones podría reducirse. Se han evaluado las técnicas NAT para el tamizaje de hepatitis B en donantes de sangre. Se ha realizado una revisión sistemática en las bases Medline y Embase (2000-2008), así como en INAHTA, Cochrane Library y Euroscan con términos MeSH “Hepatitis B”, “Blood Transfusion”, “Blood Donors";, y “Nucleic Acid Amplification Techniques”, y la terminología libre “hepatitis b”, “hbv”, “nat”, “nat-hbv” y “nucleic acid amplification testing”. Se incluyeron doce estudios, cuatro de ellos utilizaron PCR de fabricación propia, obteniendo resultados dispares; tres emplearon Procleix® (dos determinaron muestras mediante NAT que fueron HBsAg (-), 0,05% y 0,013% y el tercero, con 135 pacientes con terapia anti-VHB y HBsAg (-), obtuvo un 80% de muestras positivas mediante técnicas NAT). Cuatro trabajos con MPX® registraron porcentajes comprendidos entre 0,083 y 0,0015. En el estudio de pruebas diagnósticas incluido, las dos técnicas resultaron tener la misma sensibilidad. Por ello, se puede afirmar que las dos técnicas NAT poseen buena capacidad de tamizaje de hepatitis B, ofreciendo resultados en sensibilidad similares y podrían constituir un avance significativo en la automatización de los bancos de sangre y aumentar la seguridad de los pacientes que reciben transfusiones.
- Published
- 2013
22. Evaluación de la eficacia y seguridad de tigeciclina en el tratamiento de infecciones del tracto respiratorio: Revisión sistemática de la literatura científica
- Author
-
Moya Cordero, Patricia, primary, Ruiz-Aragón, Jesús, additional, Molina Linde, Juan Máximo, additional, Márquez-Peláez, Sergio, additional, and Motiva Sánchez, Virginia, additional
- Published
- 2013
- Full Text
- View/download PDF
23. OP169 Implementation Of A Quality Management System In The Spanish Network Of Health Technology Assessment.
- Author
-
Márquez-Peláez, Sergio, Viguera-Guerra, Isabel, Molina-Lopez, Teresa, and Amaro, Juan-Antonio Blasco
- Abstract
Introduction: The Spanish network of health technology assessment (HTA) agencies (REDETS) is a collaboration of eight agencies, units and services, commissioned by the national and regional governments. The network coordinates work within a common methodological and work framework, guided by the principles of mutual recognition and cooperation. In 2016, a common self-assessment quality tool was developed for the implementation of an overall Quality Management System. Currently we are working on the second step that deals with actions about management, joint activities as a network, and organizational aspects of the network. Methods: A structured search strategy in the main electronic databases and a manual search in websites of networks national and international agencies were carried out in June 2017, in order to gather previous knowledge and developed standards. Through the information included in this review, and with the collaboration of all members, a group of standards for REDETS was developed. Finally, standards proposed were discussed in a face-to face meeting until an agreement was reached. Results: A proposal of 31 standards was put forward taking all the collected information. The aim of each standard was defined, and its level of compliance was specified. Those standards were grouped under nine quality criteria structured in four dimensions: (i) Responsibility and Resources, (ii) Performance and Membership, (iii) Procedures, and (iv) Relations. Conclusions: Based on the gathered information and the agreement of the all members, we developed a toolkit embracing a group of standards for the joint activities within the Spanish Network, network administration and management. It is a complementary instrument of the previous self-evaluating tool, following the establishment of an overall quality management system and under the philosophy of continuous improvement processes. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
24. VP24 The Development Of A Quality Management Tool For Health Technology Assessment Agencies In Spain.
- Author
-
Gutiérrez-Ibarluzea, Iñaki, Asua, José, Molina-Lopez, Teresa, Castro-Campos, José Luis, Garcia-Armesto, Sandra, Bono-Vega, María, Bugarín-González, Rosendo, Riobóo, Janet Puñal, Luengo-Matos, Setefilla, Brezmes-Delgado, Ana, Suton, Victoria Serra, Reynolds, Jillian Margaret, Gonzalez-Enriquez, Jesús, Serrano-Aguilar, Pedro, Trujillo-Martin, M. Mar, and Márquez-Peláez, Sergio
- Abstract
INTRODUCTION:The Spanish National Network (REDETS) is a group of eight agencies, units and services, depending on National and Regional Governments that coordinate their work within a common methodological framework, guided by the principles of mutual recognition and cooperation. The necessity of considering a Quality Management System has been detected and, consequently, a common tool for all the members needs to be developed. We describe in this study the process to achieve that goal.METHODS:Based on both a review of previous literature and the proposal for a self-evaluating tool, a group of experts from each agency through consensus have developed a tool for self-evaluation in Health Technology Assessment (HTA) agencies. Through the structure described in the handbook of the Andalusian Agency for Healthcare Quality (ACSA), each standard should have a statement or proposal that needs to also include evidence or good practices, and the corresponding evaluation questions. In separate workgroups, the definition of these proposals, evidence and evaluation questions were developed. One face-to-face meeting and two meetings via teleconference were necessary to achieve a final document with all the quality standards.RESULTS:From a proposed structure of sixty-six standards, the titles, definitions, statements and evidence as well as good practices and evaluation questions were established in workgroups with consensus among all of the members (1 - 3). The final version of the self-assessment tool was composed of sixty-eight standards, grouped in twelve quality criteria structured in four dimensions: I Responsibility, II Clients and Stakeholders, III Production Process, and IV Resources.CONCLUSIONS:Quality management requires an evaluation tool and this version, based on a systematic review and consensus, is a useful and practical instrument for developing a handbook by each member of REDETS. An online version of the tool is in process of development. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
25. PP037 Quality Criteria And Good Practices In The Health Technology Assessment Spanish Network.
- Author
-
Navarro-Palenzuela, Carmen, Molina-Lopez, Teresa, Castellano-Zurera, María Del Mar, Castro-Campos, José Luis, and Márquez-Peláez, Sergio
- Abstract
INTRODUCTION:The Spanish Network of Agencies for Health Technology Assessment (REDETS) is a group of eight agencies, units and services, depending on National and Regional Governments that coordinate their work within a common methodological framework, guided by the principles of mutual recognition and cooperation. In this work, guided by the necessity of implementing a Quality Management System, we present the process to achieve this objective.METHODS:As an initial step, a review was carried out based on a structured search strategy in the main electronic databases Medline and EMBASE, and a manual search in websites of national and international agencies (March 2016) in order to collate previous knowledge and experiences. Through the information included in this review, a proposal to create a quality, self-evaluating tool is necessary.RESULTS:In total, 800 references were found and finally 6 studies were included in the review (1-3). All had a similar structure. Some lists of good practices, classified in dimensions related to different quality aspects in Health Technology Assessment (HTA) organizations, were found. Also some information about questions for evaluating quality standards was indicated. Taking all this information, a proposal of sixty-six standard titles was put forward. These standards were then grouped into twelve quality criteria structured in four dimensions: I Responsibility, II Clients and Stakeholders, III Production Process and IV Resources.CONCLUSIONS:Based on the systematic review, we developed a proposal for a self-evaluating tool and this is the baseline for a common Quality Management System for the Spanish Network of HTA Agencies. The quality management process will require the development of a handbook by each member of REDETS that will be based on agreed quality standards. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
26. VP25 African Countries Are Working Together To Enhance Medicine Use.
- Author
-
Massele, Amos, Afriyie, Daniel, Burger, Johanita, Ezenduka, Charles, Fadare, Joseph, Kalungia, Aubrey, Kibuule, Dan, Meyer, Johanna, Ogunleye, Olayinka, Oluka, Margaret, Truter, Ilse, and Godman, Brian
- Abstract
INTRODUCTION:The socioeconomic burden of diseases is increasing in Africa. For instance in 2011, 70 percent of the world's human immunodeficiency virus (HIV) population resided in sub-Sahara Africa. There are also growing rates of Antimicrobial Resistance (AMR), which necessitates newer more expensive antibiotics adding to costs. There is also a growing burden of non-communicable diseases (NCDs), three out of four patients with hypertension currently live in low and middle income countries (LMICs), with prevalence rates up to 30 to 45 percent among adults in Africa. Alongside this, up to 70 percent of total healthcare expenditure is spent on medicines in LMICs; much of this out-of-pocket. Consequently, there is an urgent need to strengthen collaborative research to improve medicine use.METHODS:Summary of groups working together in Africa including the Medicines Utilisation Research in Africa (MURIA) group.RESULTS:African Strategies for Health identifies and advocates best practices, as well as works with others to develop sustainable solutions. Pharmacology for Africa (PharfA) organises and promotes pharmacology on the African continent, including research in clinical pharmacology, alongside the International Union of Basic and Clinical Pharmacology (IUPHAR) sub-division. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Africa co-ordinates activities from the different African country chapters. The South African Health Technology Assessment Society (SAHTAS) is a scientific and professional society for all those who produce, use, or encounter Health Technology Assessment (HTA) in Southern Africa, and the World Health Organization (WHO) International and Regional groups are improving antibiotic drug utilization capabilities in Africa. The MURIA group was established in 2015 (1). Ongoing collaborative research includes (i) initiatives to optimize antibiotic use; (ii) methods to enhance adherence to anti-infective prescribing guidance, (iii) approaches to improve adherence to HIV and NCDs; (iv) researching current anti-hypertensive utilization patterns and knowledge; (v) approaches to enhance Drugs and Therapeutic Committees (DTC) activities, and (vi) strengthening medicine utilization capabilities (2,3). These activities have already strengthened research ties across Africa.CONCLUSIONS:A number of groups are already working across Africa to enhance appropriate medicine use, and should continue. Ongoing MURIA activities include antibiotic point-prevalence studies, ongoing research into infectious diseases, NCDs and DTCs including adherence as well as the third workshop and symposium in Namibia in 2017. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
27. PP033 Patient And Public Involvement In Health Technology Assessment: The Brazilian Experience.
- Author
-
Mega, Tacila, Petramale, Clarice, Rabelo, Roberta, and Silva, Aline
- Abstract
INTRODUCTION:The National Committee for Health Technology Incorporation (CONITEC) (1) was created in 2011, when the participation of civil society in the Health Technology Assessment (HTA) process was formalized in Brazil. According to legislation, patient and public involvement (PPI) in HTA occurs through: public consultations (PC); representation of SUS (Brazilian Public Health System) users in the plenary of CONITEC and by public hearings in relevant cases. Due the incipient culture of social participation in Brazil, strategies involving better communication, direct participation and popular education were developed to broaden and qualify this participation.METHODS:•Case study about PPI strategies developed in 5 years of CONITEC•Analysis of documents and official records from the Brazilian Ministry of Health.RESULTS:Since its creation, the innovations of CONITEC regarding PPI were: creation of specific PC form to reproduce or represent the perspectives of patients and caregivers; summarized versions of technical reports written in a simplified language to improve users involvement; surveys prior to elaborating clinical guidelines, a bi-weekly educational program transmitted by streaming, and the recent launch of an HTA Users Guide and a mobile app.After the implementation of these strategies (which started in 2014), there was an increase of annual contributions, from 2,584 in 2014 to 13,619 in 2015. Most participants were patients, family members or caregivers. Surveys concerning clinical guidelines received about 3,000 contributions. There were thirty-seven published society reports until December 2016. The publication of the HTA Users Guide and other related actions increased the number of accesses to the CONITEC website and its subsection for social participation. The educational program had more than 800 online accesses in five months.CONCLUSIONS:These actions allowed expanding and qualifying PPI beyond what is legally defined, and it is possible to predict an increasingly favorable scenario regarding the patient and public participation in HTA in Brazil. [ABSTRACT FROM PUBLISHER]
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.